| INTRODUC TI ON
The landscape of hepatitis C infection (HCV+) has changed dramatically since the introduction of direct-acting antivirals (DAAs). Although some earlier regimens were contraindicated in patients with advanced chronic kidney disease (CKD), there are now treatment options available for patients with end-stage renal disease (ESRD) regardless of genotype.
1,2 However, there are considerable costs associated with DAAs, 3 and a substantial mortality burden on dialysis, 4 creating true equipoise as to whether benefits derived from early HCV treatment outweigh the risk of prolonged dialysis duration. Thus the question for physicians and patients is no longer how to treat HCV infection but rather the optimal timing with respect to kidney transplantation.
Cohort studies have demonstrated higher rates of mortality for dialysis patients with HCV both in the United States and worldwide. 5, 6 Among ESRD patients who are transplanted, HCV infection has been associated with a 44% increased risk of posttransplant mortality and allograft loss. 7 Posttransplant HCV eradication with DAAs has been embraced by the transplant community as a means to improve outcomes among HCV+ recipients, and emerging data suggest posttransplant cure may enhance patient survival.
8
As wait-time for transplantation exceeds 5 years in many parts of the country, some transplant centers have encouraged dialysis patients to forego HCV treatment until after transplantation to preserve the option to receive a kidney from an HCV-infected donor. Although the use of HCV-infected organs shortens wait-time to transplantation and increases transplant rate for HCV+ recipients, these donor organs are not universally accepted by patients and transplant centers. 9, 10 HCV-infected kidneys are more likely to be discarded and HCV has a deleterious effect on allograft outcomes in studies conducted prior to the availability of DAAs 11, 12 ; when calculating the Kidney Donor Profile Index (KDPI), HCV infection leads to a lower quality score. 13 In an era in which HCV cure is possible in nearly all patients, postponing therapy may expedite transplant and avoid the excess mortality associated with prolonged dialysis exposure.
The number of HCV-viremic donors is projected to increase, and therefore understanding the implications of HCV treatment decisions on access to transplantation is crucial. To provide guidance to patients and physicians, we undertook this Monte Carlo microsimulation to explore the relative costs and quality-adjusted life years (QALYs) associated with HCV treatment pretransplant vs posttransplant. This type of decision analysis replicates real-world experiences of actual patients, modeling an individual-level multiple disease states, including DAA treatment failure and fibrosis progression. We examined 2 regimens approved for patients with ESRD and specifically considered issues surrounding variation in local waiting time and liver fibrosis stage.
| ME THODS

| Analytic overview
We developed a Monte Carlo microsimulation model of HCV infection and kidney transplantation among HCV+ kidney-only transplant candidates to estimate the cost-effectiveness of 2 strategies: (1) treating pretransplant and (2) treating posttransplant. Outcomes simulated by our model included the following:
deaths on the waitlist, QALYs, and life expectancy. We projected lifetime medical costs assuming a health sector perspective with a 3% annual discount rate to both costs and benefits. We projected 3-and 5-year time horizon, nondiscounted, healthcare sector costs. The incremental cost-effectiveness ratio (ICER) was calculated as the additional cost divided by QALYs gained compared to the next least-expensive strategy. We interpreted ICERs using a willingness-to-pay threshold (WTP) of $100 000/QALY. 14 We defined as "dominated" and eliminated from consideration strategies that either: (1) increased cost but resulted in lower QALY (strong dominance), or (2) resulted in fewer QALYs at a higher cost/QALY gained (extended dominance). The model was simulated with cohorts of 100 000 individuals. We ran these simulations 1000 times to generate 1000 ICERs for treatment pretransplant as compared to posttransplant, which were plotted on the cost-effectiveness plane. Ninety-five percent confidence ellipses and the WTP threshold were included to assess the robustness of results.
Figures are presented in the Supplemental Materials (Figures S2-S15). We projected 3-and 5-year nondiscounted budgetary impact from the health sector perspective expressed as the undiscounted cost/1000 patients on the transplant waiting-list. Data for parameter values were obtained from national databases, clinical trials, and observational cohort studies (Table 1) .
| MODEL S TRUC TURE AND INPUTS
| Model structure
The model simulates the lifetime progression of a cohort of individuals as a series of transitions between clinically meaningful health states. hort of 100 000 people, it calculates mean outcomes for the cohort, including life expectancy, QALYs, and costs. We experimented with varying cohort sizes, running simulations using cohorts of 10 000 and 1 000 000 individuals. Inferences were confirmed.
Because the model is a micro-simulation, rather than a Markov, [15] [16] [17] [18] it can track details of clinical history that impact future outcomes, such as prior HCV treatment history, and also allows for heterogeneity in person life courses. For example, whereas a Markov model would advance the entire cohort through liver fibrosis stages in a deterministic manner, the microsimulation allows for person-level variance in fibrosis progression such that some individuals progress quickly from HCV infection to cirrhosis, whereas others never reach advanced liver disease. 
| Natural history
| HCV disease progression
| Simulation of ESRD and nonliver mortality
Throughout the simulation, individuals experience decreased quality of life, costs, and mortality related to ESRD. The Scientific Registry of Transplant Recipients (SRTR) Annual Data Report provided the probability of mortality on the kidney waitlist. 4 The model assumes that the probability of waitlist mortality remains constant throughout the analysis.
| HCV treatment
We model the 2 treatment regimens available to patients with ESRD:
glecaprevir/pibrentasvir and grazoprevir/elbasvir. In the base case, patients receive glecaprevir/pibrentasvir as their initial regimen. When disaggregated from background mortality, ESRD-specific mortality, and HCV-based mortality, the probability of death was less than zero.
TA B L E 1 Transition probabilities and model inputs for the Monte Carlo simulation evaluating the costeffectiveness of HCV treatment timing among kidney transplant candidates Duration of treatment is 12 weeks, with outcomes derived from cohort studies and clinical trials. Upon initiation, patients complete 12 weeks of treatment, halting only for withdrawal, major toxicity, or death. Individuals can experience nontreatment ending toxicity, for which they incur additional costs. If an individual fails to achieve sustained viral response (SVR) on glecaprevir/pibrentasvir for any reason other than death, he is started on a 12-week regimen of grazoprevir/elbasvir (Table 2) .
HCV cure halts fibrosis progression and HCV-attributable costs decrease by 50%. 20, 25 Following cure, liver-attributable mortality is reduced by 94% among those with cirrhosis. 26 The residual liver mortality after HCV cure among cirrhotics reflects observed rates of hepatocellular carcinoma.
| Dialysis and transplant
The simulation begins with all cohort members on the transplant (Tables 1 and 2 ). 9, 10 The model assumes waitlist mortality and transplant probabilities among candidates who have achieved SVR is equivalent to HCV-negative candidates.
During the month of kidney transplant, individuals experience increased mortality, decreased quality of life, and elevated costs related to the transplant procedure itself. Following successful kidney transplant, ESRD mortality is decreased by 24%, and transplant costs decrease to reflect costs associated with transplant maintenance.
27,28
| Utilities
Quality of life in every month is a function of 3 independent utility functions: (1) liver-related, (2) ESRD-related, and (3) age-and sexadjusted comorbidities. These independent functions are integrated using a multiplicative assumption.
| Costs
The model generated costs from the health sector perspective. (Table 3) .
| Model inputs
The simulated HCV+ waitlist cohort has a median age of 57 (interquartile range [IQR] 52-62), is 73.6% male and 52.8% African
American with a median METAVIR fibrosis score of 2 (IQR 1-3) ( Figure S1 ). 10 Time to transplant among candidates treated pretransplant was informed by SRTR Program Specific Reports, which provide median time to deceased donor transplant and annual deceased donor transplant rate for each OPO. 30 Kucirka et al reported that HCV+ candidates accepting HCV-infected organs were transplanted one year more quickly than HCV− candidates who were in the pre-DAA era, supporting shorter waiting times for untreated HCV+ candidates. 9 Mortality with cirrhosis was informed by a cohort study of HCV+ cirrhotic individuals in the pre-DAA era and by multivariable adjusted time-to-event analyses. 24 Reduction in cirrhosis mortality post-SVR was reported in a cohort study using multivariable Cox proportional hazards. 26 Roth et al conducted a randomized study of grazoprevir-elbasvir among adults with stage 4 or 5 CKD, informing the treatment efficacy parameters (SVR, withdrawal, and toxicity). [41] [42] [43] [44] [45] [46] [47] [48] SVR, Sustained viral response.
| Analyses
In the base case analysis we populated the model with best estimates for every parameter and then simulated the lifetime outcomes of the cohort assuming: (1) all patients were treated prior to kidney transplant, (2) all patients were treated posttransplant, and (3) all patients were treatment-naive. We conducted stratified analyses in which we considered the decision for cohorts by liver fibrosis stage. Sensitivity analyses were conducted and our inferences were confirmed (described in greater detail in the Supplemental Materials).
| RE SULTS
| Clinical outcomes
In the pretransplant treatment strategy, 97.9% achieved cure of HCV with the primary regimen. Overall 28.0% died on the waitlist and 58.2% achieved transplantation in the lifetime horizon model. Life expectancy was 164.5 months and treatment afforded an additional 65.6 quality-adjusted life month (QALM). The total cost associated with treatment pretransplant was $735 600 (Table 4 ).
In the posttransplant treatment strategy, 98.5% of those (Table 4 ).
| Overall cost-effectiveness
Overall, treating pretransplant was associated with increased $391 560 600) ( Table 4 ).
| Cost-effectiveness by fibrosis stage
When stratified by fibrosis stage, the optimal strategy differed for cirrhotic vs noncirrhotic individuals. Among those who entered the simulation with earlier stage fibrosis (F0-F2), treating TA (Table 4 , Figures 1 and 2) . The cost-effectiveness results were consistent, even when assuming a 1.1-fold increased risk of death among HCV-infected candidates (Table S1 ).
| Cost-effectiveness by wait time
Treating pretransplant yielded more QALM until HCV+ candidates were likely to achieve transplantation 24 months more quickly (Table 6 , Figure 3 ). 
TA B L E 4 Cost-effectiveness of treatment strategies for hepatitis C virus infection among kidney waitlist candidates by fibrosis stage at waitlist addition
| Cost-effectiveness by waitlist mortality
When annual mortality rate on dialysis ranged from 3% to 6%, a trend toward increasing ICERs was noted. As previously noted, treatment posttransplant was consistently cost-saving, whereas treatment pretransplant afforded a greater number of QALMs. However, the difference in effectiveness of treatment strategy was not sufficiently substantial to designate treatment pretransplant cost-effective. In fact, the cost of treating pretransplant per QALY gained increased substantially with greater dialysis mortality (3% ICER: $155 600; 6% ICER: $162 800; 12% ICER:
$188 000; 18% ICER: $242 600; 24% ICER: $303 800) ( Table 7) . These inferences were consistent even when assuming a 1.1-fold increased risk of death among HCV-infected candidates (Table S3) .
| D ISCUSS I ON
We The reason to delay HCV therapy is to preserve a patient's option to accept an HCV-viremic organ, and thereby accelerate transplantation. HCV-viremic donors provide more than 800 kidneys per year to the deceased donor pool, and this contribution is projected to increase in light of the opioid epidemic affecting many parts of the United States. 31, 32 However, the magnitude of that benefit varies, as not all transplant centers utilize HCV-viremic organs and many potential HCV-infected donors are not pursued for organ donation. Given the projected increase in availability of HCV-infected donors, it is imperative that all centers use HCV-infected organs whenever appropriate. However, for patients listed at centers not utilizing HCV-infected organs, and therefore without access to them, pretransplant HCV treatment would instead be appropriate.
For patients with advanced liver disease, the calculus is different. Although they are still at risk for dialysis-related mortality and benefit from prompt transplantation, in our model the relative contribution of mortality risk from liver disease outweighed those associated with dialysis. They should be treated pretransplant in order to preserve their candidacy for a kidney transplant alone, and this is especially true of those in long-wait areas.
It also bears discussion that this decision analysis may be impacted by the considerable costs of DAAs in the United States.
Although health plans and insurers do not pay the publically quoted cost for these medications, and we have used the average wholesale pricing (AWP) to estimate costs in our models, the financial burden associated with HCV cure remains significant. HCV-infected kidneys shorten dialysis duration and provide an opportunity to mitigate waitlist mortality. If more favorable pricing-in line with the very low generic drug costs available in the developing world-could be obtained, insurance coverage and the cost of treatment would be less influential in the decision, possibly leading to increased rates of transplantation due to greater usage of HCV− infected organs.
Our findings are somewhat in contrast to a recent Markov decision analysis by Kiberd et al, 33 which found that pretransplant treatment of HCV was preferred, as it afforded patients more life-years, except in cases of patients with "low" HCV-related mortality or with access to HCV-infected organs. There are several essential methodologic differences in our studies that may account for the variation in findings: (1) Kiberd et al used general dialysis and wait-list mortality estimates, rather than rates specific to wait-listed HCV+ candidates;
(2) they did not model liver disease by fibrosis stage, despite marked increase in patient mortality with advancing fibrosis stage; (3) they did not account for relative differences in transplantation rates at the OPO level; and (4) they assumed that all patients were cured, TA B L E 6 Cost-effectiveness of treatment strategies for hepatitis C virus infection among kidney waitlist candidates by fibrosis stage at waitlist addition and time to transplant (HCV+ candidates transplanted a year more quickly than HCV− candidates) There are limitations to our study. This is a simulation of out- 
